Menu
Menu
The composition of NervGen’s Board and Committees are as follows:
* indicates independent non-executive board member
| Director | Board | Audit | Compensation | Nominating and Corporate Governance | Science |
|---|---|---|---|---|---|
| Brian Bayley* |  | | | ||
| Glenn Ives |  | ||||
| Randall Kaye* | | | |||
| Mike Kelly | | ||||
| Neil Klompas* | | | |||
| Krista McKerracher* | | | | | |
| Harold Punnett* | | | | ||
| Adam Rogers | | | |||
| John Ruffolo* | | | |||
| Craig Thompson* | | | |
NervGen (TSX-V: NGEN, OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to enable nervous system repair in the settings of traumatic injury and disease. NervGen’s lead drug candidate, NVG-291, is being evaluated in a Phase 1b/2a clinical trial in the company’s initial target indication, spinal cord injury. NervGen has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury.
Contact
112-970 Burrard Street
Unit 1290
Vancouver, BC V6Z 2R4
Phone: (778) 731-1711
Email: info@nervgen.com